Improving Overall Survival and Response Rates in HCC With Tumor Targeting
Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma.
Eleni Gkika, MD, a radiation oncologist at the University Medical Center Freiburg, discusses the future of treatment for patients with advanced hepatocellular carcinoma (HCC).
According to Gkika, sorafenib (Nexavar) is no longer the standard of care for advanced HCC. The IMbrave-150 study (NCT03434379) established the immunotherapy combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) as the current standard of care.
However, Gkika says that results for this combination is still not good in terms in overall survival and response rate. Tumor targeting fields have been found to be effective against several types of aggressive cancers. The HEPANOVA study (NCT03606590) aims to determine if this is correct for advanced HCC as well.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
FDA Accepts NDA Resubmission of Rivoceranib and Camrelizumab in HCC
October 21st 2024The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic hepatocellular carcinoma is supported by the final survival analysis of CARES-310 trial.
Read More
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
